Source虎嗅•Stalecollected in 34m
FDA Approves First Oral PCSK9 Inhibitor for Cholesterol
A breakthrough in oral biologics: see how cyclic peptides are replacing injections in the cholesterol market.
30-Second TL;DR
What Changed
Enlicitide is the first oral PCSK9 inhibitor, utilizing a cyclic peptide structure.
Why It Matters
This drug could disrupt the multi-billion dollar cholesterol market by replacing cumbersome injections with daily oral pills, potentially increasing patient adherence.
What To Do Next
If you are in biotech, research the cyclic peptide synthesis platform used by Merck to understand the future of oral biologics.
Who should care:Researchers & Academics
Key Points
- •Enlicitide is the first oral PCSK9 inhibitor, utilizing a cyclic peptide structure.
- •Clinical trials show a 56-59% reduction in LDL cholesterol, comparable to injectable antibodies.
- •Offers significant convenience and cost advantages over traditional injectable PCSK9 treatments.
Deep Insight
AI-generated analysis for this event — not the original article.
Enhanced Key Takeaways
- •MK-0616 utilizes a macrocyclic peptide design that overcomes the traditional challenge of oral bioavailability for large molecules, which are typically degraded in the gastrointestinal tract.
- •The FDA approval is supported by the Phase 3 CORAL-Reaching trial, which demonstrated sustained LDL-C lowering efficacy over 52 weeks in patients with hypercholesterolemia.
- •Merck's oral formulation targets the PCSK9 protein by preventing its interaction with the LDL receptor, effectively mimicking the mechanism of monoclonal antibodies without the need for cold-chain storage.
- •The drug is indicated for use as an adjunct to diet and maximally tolerated statin therapy in adults with primary hyperlipidemia or heterozygous familial hypercholesterolemia.
- •Unlike injectable PCSK9 inhibitors that require subcutaneous administration, Enlicitide's oral delivery mechanism is expected to significantly improve patient adherence rates in long-term cardiovascular disease management.
Competitor Analysis
Administration
- Enlicitide (MK-0616)
- Oral (Daily)
- Repatha (Evolocumab)
- Subcutaneous (Monthly/Bi-weekly)
- Praluent (Alirocumab)
- Subcutaneous (Monthly/Bi-weekly)
Molecule Type
- Enlicitide (MK-0616)
- Macrocyclic Peptide
- Repatha (Evolocumab)
- Monoclonal Antibody
- Praluent (Alirocumab)
- Monoclonal Antibody
Storage
- Enlicitide (MK-0616)
- Room Temperature
- Repatha (Evolocumab)
- Refrigerated
- Praluent (Alirocumab)
- Refrigerated
Primary Indication
- Enlicitide (MK-0616)
- Hypercholesterolemia
- Repatha (Evolocumab)
- ASCVD / HeFH / HoFH
- Praluent (Alirocumab)
- ASCVD / HeFH
| Feature | Enlicitide (MK-0616) | Repatha (Evolocumab) | Praluent (Alirocumab) |
|---|---|---|---|
| Administration | Oral (Daily) | Subcutaneous (Monthly/Bi-weekly) | Subcutaneous (Monthly/Bi-weekly) |
| Molecule Type | Macrocyclic Peptide | Monoclonal Antibody | Monoclonal Antibody |
| Storage | Room Temperature | Refrigerated | Refrigerated |
| Primary Indication | Hypercholesterolemia | ASCVD / HeFH / HoFH | ASCVD / HeFH |
Technical Deep Dive
- Molecular Structure: MK-0616 is a synthetic macrocyclic peptide designed to bind with high affinity to the PCSK9 protein.
- Mechanism of Action: It inhibits the binding of PCSK9 to the LDL receptor (LDLR), thereby preventing LDLR degradation and increasing the clearance of LDL cholesterol from the bloodstream.
- Bioavailability Strategy: The macrocyclic structure provides metabolic stability and membrane permeability, allowing for oral absorption despite the molecule's size.
- Pharmacokinetics: Demonstrates dose-dependent LDL-C reduction with a half-life suitable for once-daily oral dosing.
Future ImplicationsAI analysis grounded in cited sources
Shift in cardiovascular treatment paradigms
The availability of an oral PCSK9 inhibitor will likely move these potent therapies from second-line specialist-prescribed injections to first-line primary care management.
Market share erosion for injectable biologics
Patient preference for oral medication over injections is expected to drive significant switching from existing injectable PCSK9 inhibitors to Enlicitide.
Timeline
2022-11
Merck announces positive Phase 2b results for MK-0616 showing significant LDL-C reduction.
2023-06
Merck initiates the Phase 3 CORAL clinical program to evaluate the safety and efficacy of MK-0616.
2025-02
Merck reports positive top-line data from the Phase 3 CORAL-Reaching trial.
2025-10
Merck submits New Drug Application (NDA) to the FDA for MK-0616.
2026-07
FDA approves Enlicitide (MK-0616) as the first oral PCSK9 inhibitor.
- 2022-11Merck announces positive Phase 2b results for MK-0616 showing significant LDL-C reduction.
- 2023-06Merck initiates the Phase 3 CORAL clinical program to evaluate the safety and efficacy of MK-0616.
- 2025-02Merck reports positive top-line data from the Phase 3 CORAL-Reaching trial.
- 2025-10Merck submits New Drug Application (NDA) to the FDA for MK-0616.
- 2026-07FDA approves Enlicitide (MK-0616) as the first oral PCSK9 inhibitor.
Weekly AI Recap
Read this week's curated digest of top AI events →
Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
The weekly digest
One email a week. Unsubscribe anytime.